Monday, August 31, 2026

Intel Stock Is 3% Down At Session Start On Monday

ViaNews Editorial Team

December 7, 2020

Intel Stock Is 3% Down At Session Start On Monday

Shares of Intel dropped 3.94% to $49.94 at 10:08 EST on Monday, after five sequential sessions in a row of gains. The Nasdaq Stock Market is rising 0.7% to $12,464.20, after two sequential sessions in a row of gains, on what up to now seems, a somewhat positive trend exchanging session today.

Intel's last close was $50.99, 38.75% under its 52-week high of $69.29.

Intel's Sales

Intel's sales growth is a negative 13.7% for the present quarter and a decline by 17.6% for the next. The company's growth estimates for the present quarter and the next is a negative 27.6% and a negative 35.2%, respectively.

Intel's Revenue

Year-on-year quarterly revenue growth declined by 4.5%, now sitting on 78.1B for the twelve trailing months.

Intel's Stock Top and Bottom Yearly Value

Intel's stock is valued at $49.94 at 10:08 EST, way below its 52-week high of $69.29 and way higher than its 52-week low of $43.61.

Intel's Moving Average

Intel's worth is above its 50-day moving average of $47.56 and under its 200-day moving average of $52.95.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com